著者: ZhangQichen, XiePeng, HouXiaoming, ZhaoChengpeng, DuanLing, QiaoHui

原題: Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report.

著者: SebastianMartin, RydénAnna, WaldingAndrew, PapadimitrakopoulouVassiliki

原題: Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer.

著者: ShujunWang, LiliLou, LeiYang, FengWang, HefengZhan

原題: Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report.

著者: HirabayashiRyosuke, FujimotoDaichi, SatsumaYukari, HirabatakeMasaki, TomiiKeisuke

原題: Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report.

著者: GriesingerF, RadkeS, LüersA, Deschler-BaierB, KimmichM, SebastianM, SchulzC, BruggerW, WiewrodtR, PirkerR, FrühM, GautschiO, WolfJ

原題: [Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example].

著者: RydénAnna, BlackhallFiona, KimHye Ryun, PillaiRathi N, BraamLauren, MartinMona L, WaldingAndrew

原題: Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy.

著者: WuYi-Long, TsuboiMasahiro, JohnThomas, GroheChristian, MajemMargarita, GoldmanJonathan W, LaktionovKonstantin, KimSang-We, KatoTerufumi, VuHuu-Vinh, LuShun, LeeKye-Young, AkewanlopCharuwan, YuChong-Jen, de MarinisFilippo, BonannoLaura, DomineManuel, ShepherdFrances A, ZengLingmin, HodgeRachel, AtasoyAjlan, RukazenkovYuri, HerbstRoy S

原題: A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.

著者: WangJie, ChengXianYe, LuYan, ZhouBingRong

原題: A case report of toxic epidermal necrolysis associated with AZD-9291.

著者: HuangJing, MengLong, YangBing, SunShusen, LuoZhigang, ChenHong

原題: Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.

著者: LuShun, ShihJin-Yuan, JangTae-Won, LiamChong-Kin, YuYongfeng

原題: Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.

著者: AlsharediM, BukamurH, ElhamdaniA

原題: Osimertinib for the treatment of patients with <i>EGFR</i> mutation-positive non-small cell lung cancer.

著者: ShinEunhae, LimDong Hui, HanJisang, NamDo-Hyun, ParkKeunchil, AhnMyung-Ju, KangWon Ki, LeeJeeyun, AhnJin Seok, LeeSe-Hoon, SunJong-Mu, JungHyun Ae, ChungTae-Young

原題: Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.

著者: JiangTing, LuoYiyang, WangBinbin

原題: Almonertinib-induced interstitial lung disease: A case report.

著者: McLoughlinErin M, GentzlerRyan D

原題: Epidermal Growth Factor Receptor Mutations.

著者: GossGlenwood, TsaiChun-Ming, ShepherdFrances A, BazhenovaLyudmila, LeeJong Seok, ChangGee-Chen, CrinoLucio, SatouchiMiyako, ChuQuincy, HidaToyoaki, HanJi-Youn, JuanOscar, DunphyFrank, NishioMakoto, KangJin-Hyoung, MajemMargarita, MannHelen, CantariniMireille, GhiorghiuSerban, MitsudomiTetsuya

原題: Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

著者: KimYounjoo, QuachAndrew, DasSoumita, BarrettKim E

原題: Potentiation of calcium-activated chloride secretion and barrier dysfunction may underlie EGF receptor tyrosine kinase inhibitor-induced diarrhea.

著者: ChaibImane, CaiXueting, LligeDavid, SantarpiaMariacarmela, Jantus-LewintreEloisa, FilipskaMartyna, PedrazCarlos, CuiJean, YangJie, MiaoJing, SunRongwei, BrachtJillian Wilhelmina Paulina, ItoMasaoki, Codony-ServatJordi, KarachaliouNiki, AguilarAndrés, RosellRafael, CaoPeng

原題: Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma.

著者: FerroAlessandra, FiloniAngela, PavanAlberto, PaselloGiulia, GuarneriValentina, ContePierFranco, AlaibacMauro, BonannoLaura

原題: Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in <i>EGFR</i>-Mutated Non-small Cell Lung Cancer: A Case Report.

著者: AschenbrennerDiane S

原題: New Adjuvant Drug for Lung Cancer.

著者: ThomasQuentin Dominique, FirminNelly, MbatchiLitaty, EvrardAlexandre, QuantinXavier, LeenhardtFanny

原題: Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key.

著者: KomadaFusao

原題: [Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].

著者: HäntschelMaik, NieblingJohannes, HäringAlmut, HäringMax-Felix, GroßThorben, HorgerMarius, RiessenReimer, HaapMichael, LewisRichard A, BöckelerMichael, HetzelJürgen

原題: Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer.

著者: Giroux LeprieurEtienne, CortotAlexis B, CadranelJacques, WislezMarie

原題: [Osimertinib (Tagrisso^&#174;): Activity, indication and modality of use in non-small cell lung cancer].

著者: ZhangXu, MaityTapan K, RossKaren E, QiYue, CultraroConstance M, BahtaMeriam, PittsStephanie, KeswaniMeghana, GaoShaojian, NguyenKhoa Dang P, CowartJulie, KirkaliFatos, WuCathy, GuhaUdayan

原題: Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.

著者: SawantShruti S, PatilSuyash M, ShuklaSnehal K, KulkarniNishant S, GuptaVivek, KundaNitesh K

原題: Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation.

著者: YinYanchao, ShuYamin, ZhuJunru, LiFeie, LiJuan

原題: A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.